Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study

Schulman, 2010, Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding, J Thromb Haemost, 8, 641, 10.1111/j.1538-7836.2010.03737.x Fontana, 2007, New antiplatelet strategies in atherothrombosis and their indications, Eur J Vasc Endovasc Surg, 34, 10, 10.1016/j.ejvs.2007.01.004 Bonvini, 2009, Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance, Curr Vasc Pharmacol, 7, 198, 10.2174/157016109787455662 Gori, 2008, Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug‐eluting stents, J Am Coll Cardiol, 52, 734, 10.1016/j.jacc.2008.05.032 Cattaneo, 2007, Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection, J Thromb Haemost, 5, 230, 10.1111/j.1538-7836.2007.02498.x Lev, 2006, Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance, J Am Coll Cardiol, 47, 27, 10.1016/j.jacc.2005.08.058 Cuisset, 2009, Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response, Thromb Res, 123, 597, 10.1016/j.thromres.2008.04.003 Cuisset, 2006, High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome, J Thromb Haemost, 4, 542, 10.1111/j.1538-7836.2005.01751.x Linden, 2007, Indices of platelet activation and the stability of coronary artery disease, J Thromb Haemost, 5, 761, 10.1111/j.1538-7836.2007.02462.x Patrono, 1980, Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects, Thromb Res, 17, 317, 10.1016/0049-3848(80)90066-3 Patrono, 2007, Drug insight: aspirin resistance – fact or fashion?, Nat Clin Pract Cardiovasc Med, 4, 42, 10.1038/ncpcardio0728 Fontana, 2006, Biological effects of aspirin and clopidogrel in a randomized cross‐over study in 96 healthy volunteers, J Thromb Haemost, 4, 813, 10.1111/j.1538-7836.2006.01867.x Frelinger, 2008, Aspirin ‘resistance’: role of pre‐existent platelet reactivity and correlation between tests, J Thromb Haemost, 6, 2035, 10.1111/j.1538-7836.2008.03184.x Aleil, 2005, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, 85, 10.1111/j.1538-7836.2004.01063.x Frere, 2007, ADP‐induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non‐ST elevation acute coronary syndrome, Thromb Haemost, 98, 838, 10.1160/TH07-04-0296 Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator‐stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study, J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 Cuzick, 1985, A Wilcoxon‐type test for trend, Stat Med, 4, 87, 10.1002/sim.4780040112 Hosmer, 1989 Akaike, 1973, Information theory and an extension of the maximum likelihood principle, 267 Eikelboom, 2002, Aspirin‐resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation, 105, 1650, 10.1161/01.CIR.0000013777.21160.07 Angiolillo, 2009, Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus, Best Pract Res Clin Endocrinol Metab, 23, 375, 10.1016/j.beem.2008.12.001 Maree, 2005, Platelet response to low‐dose enteric‐coated aspirin in patients with stable cardiovascular disease, J Am Coll Cardiol, 46, 1258, 10.1016/j.jacc.2005.06.058 Cox, 2006, Effect of enteric coating on antiplatelet activity of low‐dose aspirin in healthy volunteers, Stroke, 37, 2153, 10.1161/01.STR.0000231683.43347.ec Fontana, 2008, Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness, Thromb Res, 121, 463, 10.1016/j.thromres.2007.06.012 Russo, 2007, Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator‐stimulated phosphoprotein, Clin Chem, 53, 1053, 10.1373/clinchem.2006.076208 Heitmann, 1990, Evaluation of body fat estimated from body mass index, skinfolds and impedance. A comparative study, Eur J Clin Nutr, 44, 831 Markuszewski, 2006, Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub‐optimal platelet response to aspirin?, Basic Clin Pharmacol Toxicol, 98, 503, 10.1111/j.1742-7843.2006.pto_343.x Gurbel, 2006, Effect of clopidogrel with and without eptifibatide on tumor necrosis factor‐alpha and C‐reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study, J Am Coll Cardiol, 48, 2186, 10.1016/j.jacc.2005.12.084 Cerletti, 2003, Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes, Clin Pharmacokinet, 42, 1059, 10.2165/00003088-200342120-00004 Hart, 2003, Aspirin dosage and thromboxane synthesis in patients with vascular disease, Pharmacotherapy, 23, 579, 10.1592/phco.23.5.579.32206 Armstrong, 2008, Aspirin and the in vitro linear relationship between thromboxane A(2) mediated platelet aggregation and platelet production of thromboxane A(2), J Thromb Haemost, 6, 1933, 10.1111/j.1538-7836.2008.03133.x Royston, 2009, Prognosis and prognostic research: developing a prognostic model, BMJ, 338, b604, 10.1136/bmj.b604 Fang, 2008, Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation, J Am Coll Cardiol, 51, 810, 10.1016/j.jacc.2007.09.065 Geisler, 2008, The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score, J Thromb Haemost, 6, 54, 10.1111/j.1538-7836.2007.02812.x Breet, 2010, Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation, JAMA, 303, 754, 10.1001/jama.2010.181 Hulot, 2006, Cytochrome P450 2C19 loss‐of‐function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Shuldiner, 2009, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, 849, 10.1001/jama.2009.1232 Hochholzer, 2010, Impact of cytochrome P450 2C19 loss‐of‐function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement, J Am Coll Cardiol, 55, 2427, 10.1016/j.jacc.2010.02.031